Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-conjugating enzyme E2 D1 (UBE2D1) is a member of the UbcH5 family of E2 enzymes that mediates the transfer of ubiquitin from ubiquitin-activating enzymes (E1s) to substrate proteins, in cooperation with various E3 ubiquitin-protein ligases. It is central to the polyubiquitination process, which tags proteins for degradation by the proteasome, and helps regulate cellular processes such as the cell cycle, DNA damage repair, immune signaling, and iron metabolism. UBE2D1’s specificity and enzymatic activity are modulated by interactions with other proteins and post-translational modifications. Dysregulation of its expression or activity is linked to several disease states, especially cancer, where it can promote degradation of tumor suppressors like p53 and influence outcomes. UBE2D1 thus represents an important point of regulation in protein homeostasis and cellular signaling.
Experimental UbVs (ubiquitin variants) bind the backside of UBE2D1, inhibiting its interaction with E1 and E3, attenuating ubiquitin chain formation on substrates. Polyubiquitination by UBE2D1 targets proteins for degradation via the proteasome, regulating the levels of numerous signaling proteins and cell cycle regulators. UBE2D1 partners with RING-type E3 ligases to catalyze ubiquitin transfer, and its conformation can influence the specificity and length of ubiquitin chains (K11, K48, K63 linkages).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 D1 (UBE2D1).